Article Text

Download PDFPDF
Improving survival in alcohol-related hepatitis: what's new?
  1. Jessica Shearer1,
  2. Amy Johnson1,
  3. Steven Masson1,2
  1. 1 Liver Unit, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
  2. 2 Translational and Clinical Research Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK
  1. Correspondence to Dr Steven Masson, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, NE7 7DN, UK; steven.masson{at}


Alcohol-related hepatitis (AH) is the most florid presentation of alcohol-related liver disease and carries a high short-term and long-term mortality rate. Specific treatment options remain inadequate. The current management approach for AH focuses on early identification, careful screening and treatment of infection, as well as identification of those patients who may benefit from corticosteroid therapy based on validated prognostic scoring systems.

In recent years, there has been growing interest in exploring novel therapies for AH, which may offer alternative treatment options beyond the traditional approaches. Additionally, early liver transplantation (LT) has emerged as a promising option in selected cases with growing evidence supporting its role. In this review, we will discuss the current evidence base for the assessment and treatment of AH, and how these advances are shaping practice to improve outcomes in the UK.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors SM was invited to write this review. SM planned the format and content of the review. JS and AJ wrote the first draft of the manuscript. SM revised the manuscript. All authors agreed to submission of the manuscript. SM is the author responsible for the overall content and the guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests SM is the BSG Clinical Lead for Alcohol and member of the BSG Liver Section. Steering committee member of the Alcohol Health Alliance, UK. Executive committee member of the Medical Council on Alcohol. Member of the DHSC Clinical Guideline Group—for Alcohol treatment. NICE Specialist Committee Member, Quality Standards in Alcohol Use Disorder. SM has received Speaker's Fees from Sandoz, Norgine Pharmaceuticals and Dr Falk Pharma within the last 3 years. JS and AJ have no competing interests.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Highlights from this issue
    R Mark Beattie